<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="548">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02041221</url>
  </required_header>
  <id_info>
    <org_study_id>SPARC_Ltd_ CLR_13_16</org_study_id>
    <nct_id>NCT02041221</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPARC1316</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sun Pharma Advanced Research company Limited has developed a dry powder inhaler of compound
      SPARC1316 for oral inhalation. This clinical study is a Phase I/IIa study to investigate the
      safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending
      doses of S0597 administered by oral inhalation to healthy volunteers and asthma patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Subjects With Adverse Events</measure>
    <time_frame>Two (2) Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The no of adverse events will be assessed to evaluate the safety and tolerability of compound SO597 in healthy male subjects and asthma patients</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>SPARC1316 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered with SPARC1316 dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The subjects will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPARC1316 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered with SPARC1316 dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPARC1316 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered with SPARC1316 dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPARC1316 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered with SPARC1316 dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPARC1316 Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered with SPARC1316 dose 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1316 Dose 1</intervention_name>
    <description>The subjects will receive SPARC1316.</description>
    <arm_group_label>SPARC1316 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>The subjects will receive a matching placebo by oral inhalation.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1316 Dose 2</intervention_name>
    <arm_group_label>SPARC1316 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1316 Dose 3</intervention_name>
    <arm_group_label>SPARC1316 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1316 Dose 4</intervention_name>
    <arm_group_label>SPARC1316 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1316 Dose 5</intervention_name>
    <arm_group_label>SPARC1316 Dose 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects willing to provide informed consent

          -  Male or female subjects aged 18 to 65 years inclusive

          -  Body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive

          -  Non-smokers or ex-smokers

        Exclusion Criteria:

          -  Subjects with a supine systolic blood pressure ≥160 mmHg and/or a supine diastolic
             blood pressure ≥100 mmHg

          -  Subjects who have a significant infection or known inflammatory process on screening
             or admission.

          -  Subjects who are unlikely to co-operate with the requirements of the study.

          -  Positive serology for infectious disease (hepatitisB or C , HIV) at screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SPARC study site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 1, 2016</lastchanged_date>
  <firstreceived_date>January 14, 2014</firstreceived_date>
  <firstreceived_results_date>December 14, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics, pharmacodynamics, asthma</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SPARC1316 Dose 1</title>
          <description>Subjects will be administered with SPARC1316 dose 1</description>
        </group>
        <group group_id="P2">
          <title>SPARC1316 Dose 2</title>
          <description>Subjects will receive SPARC1316 dose 2</description>
        </group>
        <group group_id="P3">
          <title>S0597 Dose 3</title>
          <description>Subjects will receive SPARC1316 dose 3</description>
        </group>
        <group group_id="P4">
          <title>S0597 Dose 4</title>
          <description>Subjects will receive SPARC1316 dose 4</description>
        </group>
        <group group_id="P5">
          <title>S0597 Dose 5</title>
          <description>Subjects will receive SPARC1316 dose 5</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Subjects will receive placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0">Part 1 data fields are by default copied in Part 2. There is no dose 4 and 5 actually.</participants>
                <participants group_id="P5" count="0">Part 1 data fields are by default copied in Part 2. There is no dose 4 and 5 actually</participants>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0">Part 1 data fields are by default copied in Part 2. There is no dose 4 and 5 actually</participants>
                <participants group_id="P5" count="0">Part 1 data fields are by default copied in Part 2. There is no dose 4 and 5 actually</participants>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>S0597 Dose 1</title>
          <description>Subjects will be administered with S0597
S0597: The subjects will receive S0597.
Placebo</description>
        </group>
        <group group_id="B2">
          <title>S0597 Dose 2</title>
          <description>The subjects will receive placebo.
S0597: The subjects will receive S0597.
Placebo</description>
        </group>
        <group group_id="B3">
          <title>S0597 Dose 3</title>
        </group>
        <group group_id="B4">
          <title>S0597 Dose 4</title>
        </group>
        <group group_id="B5">
          <title>S0597 Dose 5</title>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="6"/>
                <measurement group_id="B5" value="6"/>
                <measurement group_id="B6" value="10"/>
                <measurement group_id="B7" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="33" spread="3.9"/>
                <measurement group_id="B2" value="28" spread="8.2"/>
                <measurement group_id="B3" value="28" spread="4.9"/>
                <measurement group_id="B4" value="27" spread="8.8"/>
                <measurement group_id="B5" value="31" spread="5.8"/>
                <measurement group_id="B6" value="27" spread="5.3"/>
                <measurement group_id="B7" value="29" spread="6.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
                <measurement group_id="B6" value="0"/>
                <measurement group_id="B7" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="6"/>
                <measurement group_id="B5" value="6"/>
                <measurement group_id="B6" value="10"/>
                <measurement group_id="B7" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Adverse Events</title>
        <description>The no of adverse events will be assessed to evaluate the safety and tolerability of compound SO597 in healthy male subjects and asthma patients</description>
        <time_frame>Two (2) Weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>S0597 Dose 1</title>
            <description>The subjects will receive placebo.
S0597: The subjects will receive S0597.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>S0597 Dose 2</title>
          </group>
          <group group_id="O3">
            <title>S0597 Dose 3</title>
          </group>
          <group group_id="O4">
            <title>S0597 Dose 4</title>
          </group>
          <group group_id="O5">
            <title>S0597 Dose 5</title>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="6"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Adverse Events</title>
            <description>The no of adverse events will be assessed to evaluate the safety and tolerability of compound SO597 in healthy male subjects and asthma patients</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="1"/>
                  <measurement group_id="O6" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>S0597 Dose 1</title>
          <description>Subjects will be administered with S0597
S0597: The subjects will receive S0597.
Placebo</description>
        </group>
        <group group_id="E2">
          <title>S0597 Dose 2</title>
          <description>The subjects will receive placebo.
S0597: The subjects will receive S0597.
Placebo</description>
        </group>
        <group group_id="E3">
          <title>S0597 Dose 3</title>
        </group>
        <group group_id="E4">
          <title>S0597 Dose 4</title>
        </group>
        <group group_id="E5">
          <title>S0597 Dose 5</title>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>URTI</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Shravanti Bhowmik</name_or_title>
      <organization>SPARC</organization>
      <phone>+91 22 66455645</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
